EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects

Keith Rodvold iD, Mark Gotfried, Aramayis Kocharyan, Grigor Mamikonyan, Qifeng Shi, Hui Zhao, Ting Hu, Allan Xu, Meijie Le, Jianguo Li iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00524-26 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Keith Rodvold und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, beta-Lactamase Inhibitors, Cilastatin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evopoint Biosciences USA, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa . This study evaluated the intrapulmonary pharmacokinetics of funobactam, imipenem, and cilastatin in healthy subjects. Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses. Bronchoalveolar lavage (BAL) was performed at 1, 2, 4, or 6 h after the fifth dose ( n = 5 per sampling time point) to determine epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations. The means from each plasma sampling time corresponding to the BAL sampling time were used to estimate the area under the curve from 0 to 6 h (AUC 0–6h ) for plasma, and mean concentrations from BAL sampling times from each cohort were used to estimate AUC 0–6h for ELF and AM concentrations. Intrapulmonary penetration was assessed using AUC 0–6h ratios of ELF and AM to unbound plasma. The AUC 0–6h ratios of ELF to unbound plasma for funobactam, imipenem, and cilastatin were 35.2%, 31.8%, and 23.0%, respectively, and the AUC 0–6h ratios of AM to unbound plasma were 36.6%, 16.8%, and 17.9%, respectively. Funobactam penetrated ELF and AM and exhibited higher intrapulmonary penetration than imipenem and cilastatin, supporting the clinical evaluation of funobactam in combination with imipenem for the treatment of nosocomial pneumonia. This study is registered with ClinicalTrials.gov as NCT04802863 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCilastatinImipenemAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveBronchoalveolar Lavage FluidCilastatin, Imipenem Drug CombinationHealthy VolunteersLungMacrophages, Alveolar

Stichwörter der Autor:innen

XNW4107alveolar macrophagesepithelial lining fluidfunobactamintrapulmonary pharmacokinetics

Substanzen

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCilastatinCilastatin, Imipenem Drug CombinationImipenem

Autor:innen und Institutionen

  • University of Illinois Chicago, Chicago, Illinois, USA.
  • Pulmonary Associates, PA, Phoenix, Arizona, USA.
  • Clinartis LLC, Hollywood, Florida, USA.
  • Evopoint Biosciences Co., Ltd., Suzhou, China.
  • Keystone Boanalytical, LLC, North Wales, Pennsylvania, USA.
  • Evopoint Biosciences USA, Inc., Massachusetts, USA.

ORCID-Profile: Keith Rodvold, Jianguo Li

Förderung

  • Evopoint Biosciences USA, Inc

Zitieren

APA

Rodvold, K., Gotfried, M., Kocharyan, A., Mamikonyan, G., Shi, Q., Zhao, H., Hu, T., Xu, A., Le, M., & Li, J. (2026). Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00524-26

Vancouver

Rodvold K, Gotfried M, Kocharyan A, Mamikonyan G, Shi Q, Zhao H, et al. Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00524-26

BibTeX
@article{Rodvold2026,
  author = {Rodvold, Keith and Gotfried, Mark and Kocharyan, Aramayis and Mamikonyan, Grigor and Shi, Qifeng and Zhao, Hui and Hu, Ting and Xu, Allan and Le, Meijie and Li, Jianguo},
  title = {Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00524-26}
}
Kostenlos starten →